Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

Nilotinib for First-line Newly Diagnosed CML-CP Patients

NCT03942094 ·Status: UNKNOWN ·Phase: PHASE3

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

NCT02108951 ·Status: TERMINATED ·Phase: PHASE3

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

NCT04739826 ·Status: RECRUITING

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT00809211 ·Status: COMPLETED ·Phase: PHASE2

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT02272777 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients

NCT01254188 ·Status: COMPLETED ·Phase: PHASE3

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.

NCT01605981 ·Status: WITHDRAWN ·Phase: PHASE4

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

NCT00129740 ·Status: COMPLETED ·Phase: PHASE2

Nilotinib, for Patients With CML-CP or CML-AP

NCT04518644 ·Status: NO_LONGER_AVAILABLE

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib

NCT01400074 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

NCT00786812 ·Status: COMPLETED ·Phase: PHASE4

Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase

NCT00481052 ·Status: COMPLETED ·Phase: PHASE2

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

NCT00237120 ·Status: COMPLETED ·Phase: PHASE3

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

NCT00644878 ·Status: TERMINATED ·Phase: PHASE2

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

NCT01131325 ·Status: TERMINATED ·Phase: PHASE4

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367 ·Status: COMPLETED ·Phase: PHASE2

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

NCT01699217 ·Status: COMPLETED

Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia

NCT03214718 ·Status: UNKNOWN ·Phase: NA

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

NCT01511289 ·Status: COMPLETED ·Phase: PHASE3

Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients

NCT02201459 ·Status: COMPLETED ·Phase: PHASE3

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients

NCT02253277 ·Status: COMPLETED ·Phase: PHASE1

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

NCT01227577 ·Status: COMPLETED ·Phase: PHASE4

Nilotinib in PH+, BCR-, ABL+ CML Patients

NCT01535391 ·Status: COMPLETED ·Phase: PHASE3

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years

NCT02174445 ·Status: TERMINATED ·Phase: PHASE3